Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Guangxi Sun
Improved Long-Term Clinical Outcomes and Safety Profile of Sunitinib Dosing Schedule With 4/2 Switched to 2/1 in Patients With Metastatic Renal Cell Carcinoma
Journal of Cancer
Oncology
Related publications
Efficacy and Safety of Sunitinib Alternate Day Regimen in Patients With Metastatic Renal Cell Carcinoma in Japan: Comparison With Standard 4/2 Schedule
Asia-Pacific Journal of Clinical Oncology
Medicine
Oncology
Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma
European Urology
Urology
Metastatic Clear Cell Renal Cell Carcinoma With a Long-Term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression
Clinical Genitourinary Cancer
Oncology
Urology
Association of Angiopoietin-2 and Ki-67 Expression With Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma
PLoS ONE
Multidisciplinary
High-Dose Interleukin 2 in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Features
PLoS ONE
Multidisciplinary
Disparities in the Treatment of Patients With IL-2 for Metastatic Renal Cell Carcinoma
Urologic Oncology: Seminars and Original Investigations
Oncology
Urology
Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
Therapeutic Advances in Urology
Urology
Durability of Responses in Patients With Metastatic Renal Cell Carcinoma Treated With High Dose Interleukin-2 (HD IL-2)
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
